In this episode of the Applied Clinical Trials Brief, we spotlight a recent video interview with Luke Wilson of Thermo Fisher ...

Jon Walsh, founder, chief scientific officer, Unlearn, explains how AI and digital twin technologies are being applied to improve data transparency, ensure reproducibility, and strengthen the ...

Results from a Phase II trial (NCT06640972) showed that patients treated with RDX-002 experienced significant reductions in ...

In this video interview, Meri Beckwith, Co-CEO of Lindus Health, explains why sponsors pursuing breakthrough or priority ...

Bringing some payment activities in-house while outsourcing others can help sponsors optimize clinical trial efficiency, ...

In the Phase III VAYHIT2 trial, ianalumab combined with eltrombopag significantly prolonged time to treatment failure and ...

The global Phase III EMPEROR trial (NCT06872125) will evaluate the safety and efficacy of zorevunersen, a novel antisense ...

In this Phase III trial, the Padcev-Keytruda combination used as both neoadjuvant and adjuvant therapy significantly improved event-free and overall survival, as well as pathologic complete response, ...

Results from the Phase III ATTAIN-1 trial (NCT05869903) showed that the highest dose of orforglipron achieved an average ...

In the Phase III ENVISION trial, Zusduri achieved a 24-month duration of response rate of 72.2% among patients with a ...

In this video interview, Meri Beckwith, Co-CEO of Lindus Health, examines how recent developments with Complete Response ...

Company opts not to advance VX-993 into pivotal development after Phase II data show no statistically significant benefit ...